Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Coding Corner Question: Use Level 3 or 4 for RA/Gout Patient?

From the College  |  March 11, 2019

A 60-year-old man returns for a follow-up related to his diagnoses of rheumatoid arthritis and chronic gout of his right ankle and foot, without tophi. He reports the gout flares have subsided in his ankle. He takes 450 mg of allopurinol daily. He has rheumatoid factor-positive rheumatoid arthritis, which previously affected multiple sites, without organ…

Coding Corner Answer: Use Level 3 or 4 for RA/Gout Patient?

From the College  |  March 11, 2019

Take the challenge. CPT: 20611-LT, J7325-EJ ICD-10: M17.12, E66.01, Z68.41 CPT: 99213 ICD-10: M1a.0710, M05.79 History—The history of present illness was extended. The review of systems was extended, and two past family social history elements were documented. This makes the history level detailed. Examination—Five systems were examined. This makes the exam level detailed. Medical decision…

Reminder: MIPS Reporting Deadline Is April 2

From the College  |  March 7, 2019

Don’t forget: The submission window for the Quality Payment Program Performance Year 2018 closes on Tuesday, April 2, 2019. Submissions must be complete by 8:00 PM EDT. We encourage all MIPS-eligible clinicians to double-check their status and final scores with the CMS by logging into their EIDM account. Not sure how to review your final score?…

Safety Risk with Higher Dose Tofacitnib

Michele B. Kaufman, PharmD, BCGP  |  March 6, 2019

According to the FDA, an ongoing safety trial found higher dose tofacitinib increased the risks of pulmonary embolism and death in RA patients…

Rheumatoid Arthritis Risk Lower Among Smokers Who Quit

Lisa Rapaport  |  March 5, 2019

(Reuters Health)—Adults who quit smoking decades ago may have a lower risk of rheumatoid arthritis (RA) than people who gave up cigarettes more recently, a U.S. study suggests. Smoking has long been linked to an increased risk of RA, and quitting can reduce this risk. But the new study offers fresh evidence that years of…

Tainted Research Repeatedly Re-Used to Assess Drug Effectiveness

Gene Emery  |  March 5, 2019

(Reuters Health)—A new study shows how fake news—specifically, information about scientific research that may be tainted by fraud—keeps getting spread through the medical literature, misleading doctors about the safety and effectiveness of the drugs they prescribe. At issue is the failure of medical journals to flag research that’s been identified by the U.S. Food and…

Clinicians’ Use of ‘Safer’ Opioid-Prescribing Practices Spotty

Anne Harding  |  March 5, 2019

NEW YORK (Reuters Health)—Many U.S. clinicians aren’t following risk-mitigation practices for opioid prescribing, new findings show. “In response to this national opioid crisis, consensus-based safer opioid prescribing guidelines have been published and state laws regulating opioid prescribing practices have been enacted,” Daniel P. Alford, MD, of Boston University School of Medicine, and colleagues write in…

U.S. FDA Chief Gottlieb Resigns

Yasmeen Abutaleb  |  March 5, 2019

WASHINGTON (Reuters)—U.S. Food and Drug Administration (FDA) Chief Scott Gottlieb said he plans to step down in a month, calling into question how the agency will handle critical issues, such as e-cigarette use among teens and efforts to increase competition in prescription drugs. The U.S. Department of Health and Human Services (HHS), which oversees the…

ACR Addresses the Rheumatology Workforce Shortage

Kelly Tyrrell  |  March 5, 2019

Analysis of the 2015 ACR Workforce Study, published in the April 2018 issue of Arthritis Care & Research, revealed the U.S. will face a shortage of 4,000 rheumatology providers by 2030.1 This shortage will be uneven, with rheumatology providers concentrated in urban and suburban areas, and rural areas underserved. The Central U.S., Southwest, Southeast and…

Practices Now Contributing to RheumPAC

Carina Stanton  |  March 5, 2019

Last year the ACR’s nonpartisan political action committee, RheumPAC, raised nearly $150,000 from individual contributors. Starting in 2019, the addition of the RheumPAC Advocacy Fund, where rheumatology practices and state societies can contribute corporate dollars, is expected to support RheumPAC fundraising efforts in an effort to surpass this dollar amount, giving rheumatology an even stronger…

  • « Previous Page
  • 1
  • …
  • 279
  • 280
  • 281
  • 282
  • 283
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences